SR-717(AbMole,M9923)是一种非核苷酸类小分子STING激动剂,它作为环鸟苷酸-腺苷酸(cGAMP)的模拟物,诱导STING蛋白形成“闭合”构象,从而激活下游信号通路[1]。在分子水平上,SR-717( CAS No.:2375421-09-1)显著增强了STING通路的磷酸化,包括TANK结合激酶1(TBK1)、干扰素调节因子3(IRF3)和STAT3的磷酸化,并促进干扰素-β(IFN-β)的表达[2]。
在细胞模型中,SR-717 能够抑制MOD-EK细胞的凋亡,提高细胞存活率,其作用机制与STING-IL-6信号通路的激活密切相关[3]。SR-717在人类外周血单核细胞中促进树突状细胞(DCs)的成熟,并增强CD8+ T细胞、自然杀伤(NK)细胞的活化[1]。此外,SR-717还具有抗辐射活性,例如在动物实验中,C57BL/6小鼠模型显示SR-717通过腹腔给药显著提高了受辐射个体的存活率,减轻了体重下降和肠道隐窝细胞损失。其辐射保护作用与TLR2介导的STING-IL-6信号通路激活相关,TLR2基因缺失会逆转SR-717的保护效果[3]。在肿瘤模型中,
SR-717(AbMole,M9923)通过促进免疫细胞(如CD8+ T细胞和NK细胞)的浸润与活化,抑制了多种肿瘤的生长[4]。
范例详解
Chemical Engineering Journal. Volume 505. 159704
重庆医科大学在上述文章中使用了AbMole的
SR-717(AbMole,M9923)。研究人员开发了负载CaCO3的金属-有机框架(MOFs),包含Mn2+、缺氧激活前药班诺蒽醌(Banoxantrone,AQ4N)和干扰素基因刺激因子(STING)激动剂SR-717。
MOFs可在肿瘤微环境中有效积累并释放药物,利用高强度聚焦超声(HIFU)治疗后导致的缺氧条件激活AQ4N分子,诱导免疫原性细胞死亡,增强肿瘤免疫原性;Mn2+增强SR-717活性,协同放大STING激活,促进免疫细胞浸润;CaCO3消耗肿瘤微环境中的乳酸,重塑免疫微环境。实验表明,MOFs增强了HIFU术后抗肿瘤免疫反应,显著抑制小鼠体内肿瘤的复发和转移。
参考文献
[1] Chin, E. N.; Yu, C.; Vartabedian, V. F.; et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.
Science (New York, N.Y.) 2020,
369 (6506), 993-999.
[2] Shen, C.; Xu, P.; Zhang, C.; et al. Structure-Activity Relationship Study of 1H-Pyrrole-3-carbonitrile Derivatives as STING Receptor Agonists.
ACS medicinal chemistry letters 2023,
14 (8), 1079-1087.
[3] Fang, D.; Duan, W.; Zhai, X.; et al. SR-717, a Non-Nucleotide STING Agonist, Displayed Anti-Radiation Activity in a IL-6 Dependent Manner.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2025,
39 (11), e70644.
[4] Wang, H.; Liu, Z.; Fang, Y.; et al. Spatiotemporal release of non-nucleotide STING agonist and AKT inhibitor from implantable 3D-printed scaffold for amplified cancer immunotherapy.
Biomaterials 2024,
311, 122645.
[5] Zhou, Y.; Huang, X.; Wu, D.; et al. HIFU postoperative hypoxia enables metal-organic frameworks amplifying banoxantrone and STING activation for enhanced immunotherapy.
Chemical Engineering Journal 2025,
505, 159704.